NCT02562131Active, not recruiting
PET-MR-PSA Prostate Cancer Recidive Study
18F-Fluciclovine PET/MRI for Detection of Recurrent Prostate Cancer After Radical Treatment
Source: ClinicalTrials.gov · Last updated 2 Oct 2026
Brief summary (registry, in English)
Simultaneous PET/MRI has the potential to improve the detection accuracy in recurrent prostate cancer, since it combines the excellent soft-tissue contrast of MRI with the high molecular sensitivity of PET in a single imaging session. The aim of this study is to evaluate the sensitivity and specificity of simultaneous 18F-Fluciclovine PET/MRI for detection of recurrent prostate cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 80 (actual)
- First submitted
- 25 Sept 2015
- Start date
- Sept 2015
- Primary completion date
- Dec 2027
- Lead sponsor
- Norwegian University of Science and Technology
- Diseases
- Prostate cancer
- NCT number
- NCT02562131
What you commit to
- Study type: Observational
- Participants enrolled: 80
- From Sept 2015 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- impaired renal function defined as estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73 m2
Other
- general contra-indications for a PET/MRI exam (pacemaker, aneurysm clips, any form of metal in the body, or severe claustrophobia)
Who the study is looking for
- the criteria for biochemical relapse in accordance with the European Association of Urology (EAU) guidelines on prostate cancer must be fulfilled (two consecutive measurements with PSA \> 0.2 ng/ml following radical prostatectomy or PSA \> 2.0 ng/ml above the nadir following definitive radiotherapy)
- potential candidates for salvage treatment based on age and co-morbidity.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St Olavs Hospital, PET center Coordinator of this site? Confirm its status | Trondheim | Norway | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.